SEC Tracker
Get the app

Coherus Oncology CHRS

Coherus Oncology Q1 FY25: net loss $56.6M; diluted EPS −$0.49

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Coherus Oncology reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$56.6M−155% from $102.9M in Q1 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.49−159% from $0.83 in Q1 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$82.4M−68% from $259.8M in Q1 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$25.8MAgainst −$46.8M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Coherus Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Entera Bio ENTX public float $85M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025